Preliminary Annual Report 2008

Doubled EBIT and 56 percent increase of net sales

• Net sales for the year amounted to 68.0 million SEK (43.6) and for the fourth quarter to 15.7 million SEK (13.0).
• EBIT for the year amounted to 10.2 million SEK (5.2) and for the fourth quarter to 2.5 million SEK (1.2).
• Profit after tax for the year amounted to 8.0 million SEK (24.5) and for the fourth quarter to 1.4 million SEK (19.7).
• Earnings per share for the year amounted to 0.85 SEK (2.62) and for the fourth quarter to 0.15 SEK (2.11).
• Cash flow for the year amounted to 13.9 million SEK (13.0).
• Breakthrough in USA through Next Food’s and Kraft Food’s launch of probiotic based products.
• Successful common cold study gives possibility for product launches within the immune area during 2009.
• New agreements in the fourth quarter through Probi’s partner Institut Rosell for the sales of dietary supplements based on Probi’s Lp299v in Spain and Belgium.
• Probi received a research grant in the amount of 1.8 million SEK from Vinnova for research during 2009 and onward about probiotics’ positive health effects within the cardiovascular field.
• Cooperation with Dr. Oz and HealthCorps in order to increase health awareness among teenageers in USA.

CEO’s comments:
”2008 became a breakthrough year for Probi. We have doubled EBIT and increased net sales by 56 percent. Additionally, we have expanded business geographically as well as product-wise. A large number of agreements within Funcational Food and Dietary Supplements have been made and we count on launcheing our new immune product during 2009. We see a large potential in this product and it conveys the strength and width of Probi’s research,” says Michael Oredsson, CEO of Probi.

For further information, contact:
Michael Oredsson, CEO, Probi, phone: +46 (0)46 286 89 23 or +46 (0)707 18 89 30,
e-mail: michael.oredsson@probi.se

Distributed Jan. 28th, 2009. 8.45 (CET)